Epigral Limited has filed its audited financial results for Q4FY26 with the National Stock Exchange and BSE Limited under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The company reported highest ever quarterly revenue of ₹736.16 crore and recommended a final dividend of ₹5 per share, representing 50% of face value of ₹10. The Board meeting was held on May 2, 2026, at the registered office in Ahmedabad.

Conference Call Recording Available

Following the Q4FY26 results announcement, Epigral Limited has made available the audio recording of the conference call discussing the quarterly results. The conference call was held on Saturday, May 2, 2026 at 4:30 p.m. In compliance with Regulation 30 of SEBI (LODR) Regulations, 2015, the company has provided access to the audio recording through its official website. The recording is available at the company's results section and provides detailed discussions on the Q4FY26 performance.

Operational Performance Highlights

The company demonstrated strong operational metrics with 15% sequential sales volume growth and plant utilization exceeding 80% in Q4FY26. This operational efficiency contributed significantly to the revenue recovery and improved financial performance during the quarter. The Derivatives & Specialty business contributed 54% of revenue in Q4FY26 compared to 52% in Q3FY26.

Q4FY26 Financial Performance

The fourth quarter demonstrated exceptional performance with revenue reaching ₹736.16 crore, marking a 17% YoY growth from ₹627.63 crore in Q4FY25. On sequential basis, the company witnessed strong recovery with 22% QoQ growth from ₹597.12 crore in Q3FY26. PAT stood at ₹81.93 crore for the quarter, showing 109% QoQ improvement from ₹39.15 crore in Q3FY26. EBITDA for the quarter was ₹169 crore with a margin of 23%.

FY2026 Annual Performance and Capex Plans

For the full year, revenue stood at ₹2,542.16 crore, a 1% decline from ₹2,565.34 crore in FY2025 due to a 4% drop in sales volume. PAT for FY26 was ₹333.01 crore compared to ₹356.70 crore in FY25. The company spent ₹394.15 crore on capital expenditure in FY2026, with expansion projects progressing as per schedule. CPVC Resin capacity will reach 1,50,000 TPA by adding 75,000 TPA, while Epichlorohydrin capacity will reach 1,00,000 TPA by adding 50,000 TPA, both expected to be commissioned in H1FY27.

Management Commentary and Strategic Outlook

Maulik Patel, Chairman and Managing Director, highlighted the strong operational performance driven by 15% sequential volume growth and improved plant utilization above 80%. Patel noted that demand recovery began in November and strengthened through Q4, with momentum expected to continue into FY27 subject to global macro conditions. The company has also invested in renewable energy through agreements with Pro-Zeal Green Power Ten Private Limited for a 19.80 MW Wind Solar Hybrid Power Plant in Gujarat.

Regulatory Filing and Recognition

The audited financial results were approved by the Board on May 2, 2026, and filed by Company Secretary & Compliance Officer Gaurang Trivedi. The statutory auditors M/s. S R B C & CO LLP issued audit reports with unmodified opinion. Epigral has been awarded the EcoVadis Silver Medal and its Responsible Care certification has been renewed for another three years. The company is expanding its Wind Solar Hybrid Power Plant capacity to 38.14 MW by adding 19.80 MW, demonstrating commitment to sustainable operations.

Epigral Limited has issued a postal ballot notice seeking shareholder approval for the reappointment of three Non-Executive Independent Directors for their second consecutive terms. The board of directors approved these appointments through a circular resolution dated April 16, 2026, following recommendations from the Nomination and Remuneration Committee.

E-Voting Schedule and Process

The company has engaged Central Depository Services (India) Limited (CDSL) to provide e-voting facility to its members. The postal ballot notice has been sent electronically to members whose email addresses are registered with the company or their Depository Participants.

Director Reappointment Details

All three directors are being reappointed for their second term of five consecutive years, effective from May 20, 2026, to May 19, 2031. The appointments require shareholder approval through special resolutions.

Director Profiles and Expertise

Mr. Sanjay Asher (DIN: 00008221) brings extensive legal expertise as a Senior Partner with Crawford Bayley and Co., India's oldest law firm established in 1830. He specializes in mergers and acquisitions, cross-border M&A, joint ventures, private equity, and capital markets. He holds Bachelor's degrees in Commerce and Law from the University of Bombay, is a qualified Chartered Accountant, and was admitted as a Solicitor in 1993. He received ₹7.75 lakh as sitting fees during FY 2025-26.

Mr. Kanubhai Patel (DIN: 00008395) contributes over three decades of experience in finance, marketing, and commercial matters. His career includes serving as Executive Director since 1995, Joint Managing Director from 2002, and Chairman and Managing Director from 2013 at Voltamp Transformers Limited. He holds a Bachelor's degree in Commerce and is a Fellow Member of both the Institute of Chartered Accountants of India and the Institute of Company Secretaries of India. He received ₹8.50 lakh as sitting fees during FY 2025-26.

Mr. Raju Swamy (DIN: 03032679) brings over 40 years of experience in family business consulting through PROMAG Consultancy Services. His expertise covers structure, strategy, governance, trust, ownership, professionalization, continuity, succession, and growth aspects of family businesses. He holds an MBA from IIM Calcutta's first batch and received ₹4.75 lakh as sitting fees during FY 2025-26. His reappointment also requires special approval as he has attained 75 years of age.

Regulatory Compliance and Process

The reappointments comply with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. All three directors have confirmed their independence and submitted necessary declarations regarding their eligibility and compliance with regulatory requirements.